Ranibizumab for age-related macular degeneration

New England Journal of Medicine

Volumn 364, Issue 6, 2011, Pages 582-

  Cheng, Jin Wei ^a   Wei, Rui Li ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; HUMAN; INCIDENCE; LETTER; OFF LABEL DRUG USE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK BENEFIT ANALYSIS;

EID: 79851507124     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1014160     Document Type: Letter

References (3)

1. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010;340:c2459.
2. Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond) 2010;24:1708-15.
3. Sato T, Emi K, Ikeda T, et al. Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology 2010;117:512-6.